haloperidol has been researched along with Catatonic Rigidity in 53 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 9.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 9.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| "The aim of the present study was to find out whether (+/-)-8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), a prototypical 5-HT1A agonist, and (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane HCl (EMD 128130), a compound with serotonin 5-HT1A-agonist and dopamine D2-like antagonist properties, are able to attenuate the haloperidol-induced (1 mg/kg) muscle rigidity in rats." | 7.72 | Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. ( Bartoszyk, GD; Lorenc-Koci, E; Wardas, J; Wolfarth, S, 2003) |
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 7.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 7.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| " Experimental rabbits treated with haloperidol (1 mg/kg) by intramuscular injection, were studied for the diagnostic symptoms of increased muscle rigidity, elevated body temperature, and high serum creatine phosphokinase (CPK) level." | 7.69 | Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. ( Hosono, T; Ikura, Y; Kudo, T; Niigawa, H; Nishimura, T; Sakamoto, S; Takeda, M; Taniguchi, N; Tanii, H, 1996) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 5.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 5.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| " The syndrome resolved within a few days of stopping haloperidol and initiation of lorazepam." | 3.78 | Neuroleptic-induced catatonia in two hospitalized patients. ( Gugger, JJ; Saad, M; Smith, C, 2012) |
| "The aim of the present study was to find out whether (+/-)-8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), a prototypical 5-HT1A agonist, and (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane HCl (EMD 128130), a compound with serotonin 5-HT1A-agonist and dopamine D2-like antagonist properties, are able to attenuate the haloperidol-induced (1 mg/kg) muscle rigidity in rats." | 3.72 | Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. ( Bartoszyk, GD; Lorenc-Koci, E; Wardas, J; Wolfarth, S, 2003) |
| " Muscle rigidity was assessed quantitatively and objectively as increases in electromyographic (EMG) activity (muscle rigidity) in the hindlimb muscles of the rat following subcutaneous administration of haloperidol, fluphenazine and thioridazine." | 3.71 | An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. ( Crocker, AD; Hemsley, KM, 2001) |
| "The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats." | 3.71 | (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001) |
| " Parkinsonian-like muscle rigidity was induced by pretreatment with haloperidol (1 mg/kg i." | 3.70 | LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S, 1998) |
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 3.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 3.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| " Experimental rabbits treated with haloperidol (1 mg/kg) by intramuscular injection, were studied for the diagnostic symptoms of increased muscle rigidity, elevated body temperature, and high serum creatine phosphokinase (CPK) level." | 3.69 | Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. ( Hosono, T; Ikura, Y; Kudo, T; Niigawa, H; Nishimura, T; Sakamoto, S; Takeda, M; Taniguchi, N; Tanii, H, 1996) |
| "Two schizophrenic patients developed muscular rigidity, stupor, and hyperpyrexia consistent with neuroleptic malignant syndrome, 8 to 10 days after starting haloperidol therapy." | 3.66 | Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. ( Bismuth, C; Conso, F; de Rohan-Chabot, P; Elkharrat, D; Gajdos, P; Goulon, M, 1983) |
| "We measured muscular rigidity with a new method by determining the resistance of the hindlimb to passive flexion in the 'balance test' and also checked haloperidol (3 mg/kg i." | 1.31 | Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. ( Ferger, B; Fischer, DA; Kuschinsky, K, 2002) |
| "The muscle rigidity was measured as an increased resistance of a hind leg to passive extension and flexion at the ankle joint." | 1.31 | Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wierońska, J; Wolfarth, S, 2001) |
| "In a separate test, muscular rigidity is induced by the opioid, fentanyl, and subsequently, test compounds are assessed for their ability to reverse muscular rigidity." | 1.28 | An in vivo alpha-2 assay reversal of opioid-induced muscular rigidity and neuroleptic-induced ptosis. ( Benvenga, MJ; Capacchione, JF; Del Vecchio, RA; Jerussi, TP, 1992) |
| "We observed a case of NMS in which disseminated intravascular coagulation was a prominent feature." | 1.27 | Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation. ( DiPette, DJ; Eles, GR; Songer, JE, 1984) |
| "With regard to the haloperidol-induced catalepsy as measured by means of the bar test, a similar distribution of effective and ineffective injection sites was observed; however, higher doses of haloperidol (1." | 1.27 | Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. ( Cools, A; Ellenbroek, B; Jaspers, R; Schwarz, M; Sontag, KH, 1985) |
| "The haloperidol catalepsy was strongly inhibited by administration of picrotoxin to the Vm while the morphine catalepsy remained unchanged after picrotoxin." | 1.27 | Thalamus as a relay station for catalepsy and rigidity. ( Kolasiewicz, W; Ossowska, K; Wolfarth, S, 1985) |
| "The development of tolerance to the muscular rigidity produced by morphine was studied in rats." | 1.27 | On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats. ( Havemann, U; Kuschinsky, K; Themann, P, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (50.94) | 18.7374 |
| 1990's | 8 (15.09) | 18.2507 |
| 2000's | 16 (30.19) | 29.6817 |
| 2010's | 1 (1.89) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Gugger, JJ | 1 |
| Saad, M | 1 |
| Smith, C | 1 |
| Fischer, DA | 1 |
| Ferger, B | 1 |
| Kuschinsky, K | 3 |
| Thomsen, TW | 1 |
| Brown, DF | 1 |
| Nadel, ES | 1 |
| Yang, YK | 1 |
| Nelson, L | 1 |
| Kamaraju, L | 1 |
| Wilson, W | 1 |
| McEvoy, JP | 2 |
| Kiang, M | 1 |
| Daskalakis, ZJ | 1 |
| Christensen, BK | 1 |
| Remington, G | 2 |
| Kapur, S | 2 |
| Lorenc-Koci, E | 4 |
| Wardas, J | 3 |
| Bartoszyk, GD | 1 |
| Wolfarth, S | 8 |
| Yen, YC | 1 |
| Lung, FW | 1 |
| Chong, MY | 1 |
| Scherer, J | 1 |
| Dobmeier, P | 1 |
| Kuhn, K | 1 |
| Schmaus, W | 1 |
| Putzhammer, A | 1 |
| Perfahl, M | 1 |
| Pfeiff, L | 1 |
| Broll, K | 1 |
| Hess, L | 1 |
| Ibach, B | 1 |
| Sell, SL | 1 |
| McMahon, LR | 1 |
| Koek, W | 1 |
| France, CP | 1 |
| Taskapan, C | 1 |
| Sahin, I | 1 |
| Taskapan, H | 1 |
| Kaya, B | 1 |
| Kosar, F | 1 |
| Caroff, SN | 1 |
| Goekoop, JG | 1 |
| Carbaat, PA | 1 |
| Knezevic, W | 1 |
| Mastaglia, FL | 1 |
| Lefroy, RB | 1 |
| Fisher, A | 1 |
| Havemann, U | 2 |
| Goulon, M | 2 |
| de Rohan-Chabot, P | 1 |
| Elkharrat, D | 2 |
| Gajdos, P | 1 |
| Bismuth, C | 2 |
| Conso, F | 2 |
| Eles, GR | 1 |
| Songer, JE | 1 |
| DiPette, DJ | 1 |
| May, DC | 1 |
| Morris, SW | 1 |
| Stewart, RM | 1 |
| Fenton, BJ | 1 |
| Gaffney, FA | 1 |
| Samar, RK | 1 |
| Kaushik, SK | 1 |
| Garg, AR | 1 |
| Town, IG | 1 |
| de Rohan Chabot, P | 1 |
| Johnels, B | 2 |
| Steg, G | 2 |
| Factor, SA | 1 |
| Podskalny, GD | 1 |
| Barron, KD | 1 |
| Lukhanina, EP | 1 |
| Kolomietz, BP | 1 |
| Prokopenko, VF | 1 |
| Rodionov, VA | 1 |
| Tanii, H | 1 |
| Taniguchi, N | 1 |
| Niigawa, H | 1 |
| Hosono, T | 1 |
| Ikura, Y | 1 |
| Sakamoto, S | 1 |
| Kudo, T | 1 |
| Nishimura, T | 1 |
| Takeda, M | 1 |
| Viscomi, CM | 1 |
| Bailey, PL | 1 |
| Konieczny, J | 4 |
| Ossowska, K | 4 |
| Pilc, A | 3 |
| Schulze, G | 1 |
| Coper, H | 1 |
| Fitzgerald, PB | 1 |
| Caligiuri, MP | 1 |
| Jones, C | 1 |
| Silvestri, S | 1 |
| Zipursky, RB | 1 |
| Crocker, AD | 1 |
| Hemsley, KM | 1 |
| Wierońska, J | 1 |
| Tauscher, J | 1 |
| Küfferle, B | 1 |
| Asenbaum, S | 1 |
| Tauscher-Wisniewski, S | 1 |
| Kasper, S | 1 |
| Lisciani, R | 1 |
| Baldini, A | 1 |
| Ciottoli, GB | 1 |
| Ungerstedt, U | 1 |
| Geller, B | 1 |
| Greydanus, DE | 1 |
| Beasley, BA | 1 |
| Ford, DH | 1 |
| Benvenga, MJ | 1 |
| Del Vecchio, RA | 1 |
| Capacchione, JF | 1 |
| Jerussi, TP | 1 |
| van den Bos, R | 1 |
| Cools, AR | 1 |
| Aley, KO | 1 |
| Kulkarni, SK | 1 |
| Ellenbroek, B | 2 |
| Schwarz, M | 2 |
| Sontag, KH | 2 |
| Cools, A | 2 |
| Jaspers, R | 1 |
| Kolasiewicz, W | 2 |
| Kirubakaran, V | 1 |
| Anand, MM | 1 |
| Mayfield, D | 1 |
| Powell, BJ | 1 |
| Baran, J | 1 |
| Colpaert, FC | 1 |
| Stiller, RL | 1 |
| Farr, R | 1 |
| Themann, P | 1 |
| Thulin, CA | 1 |
| Blom, S | 1 |
| LANSING, AI | 1 |
| LAMY, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transdermal Nicotine in Female Patients at High Risk for PONV[NCT00775749] | 0 participants (Actual) | Interventional | 2009-04-30 | Withdrawn (stopped due to The study is not feasible with the number of subjects needed to complete it.) | |||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for haloperidol and Catatonic Rigidity
| Article | Year |
|---|---|
Aging and the extrapyramidal system.
Topics: Aged; Aging; Basal Ganglia Diseases; Chlorpromazine; Chorea; Dopamine; Frontal Lobe; Gait; Haloperid | 1976 |
6 trials available for haloperidol and Catatonic Rigidity
| Article | Year |
|---|---|
Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Anti-Dyskinesia Agents; Brain; Female; Haloperidol; Humans; Hypoki | 2002 |
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; | 2003 |
Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Topics: Adult; Blood Pressure; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; | 2004 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio | 2004 |
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Exercise Test; Femal | 2004 |
Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade.
Topics: Adult; Carbon Radioisotopes; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor | 2000 |
46 other studies available for haloperidol and Catatonic Rigidity
| Article | Year |
|---|---|
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
Neuroleptic-induced catatonia in two hospitalized patients.
Topics: Adult; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Hospitalization; | 2012 |
Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Haloperidol; | 2002 |
Pediatric tremors.
Topics: Anti-Dyskinesia Agents; Basal Ganglia Diseases; Child, Preschool; Emergencies; Haloperidol; Humans; | 2002 |
Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Haloperidol; Male; Muscle Rig | 2003 |
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys.
Topics: Adrenergic alpha-Agonists; Amphetamine; Analgesics, Opioid; Animals; Antidepressive Agents, Tricycli | 2005 |
Possible malignant neuroleptic syndrome that associated with hypothyroidism.
Topics: Adrenal Insufficiency; Antipsychotic Agents; Body Temperature; Clozapine; Female; Haloperidol; Human | 2005 |
The neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cognition Disorders; Consciousness Disorders; Diagno | 1980 |
Treatment of neuroleptic malignant syndrome with dantrolene.
Topics: Adult; Bipolar Disorder; Dantrolene; Haloperidol; Humans; Male; Malignant Hyperthermia; Muscle Rigid | 1982 |
Neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Female; Fever; Fluphenazine; Haloperidol; Humans; Male | 1984 |
Further characterization of opioid receptors in the striatum mediating muscular rigidity in rats.
Topics: Animals; beta-Endorphin; Caseins; Caudate Nucleus; Electromyography; Endorphins; Enkephalin, Leucine | 1981 |
Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Dantrolene; Fever; Haloperidol; Humans; Male; Muscle Rigi | 1983 |
Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation.
Topics: Adult; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Disseminated Intravascular Coagula | 1984 |
Neuroleptic malignant syndrome: response to dantrolene sodium.
Topics: Dantrolene; Fever; Haloperidol; Humans; Male; Middle Aged; Muscle Rigidity; Syndrome | 1983 |
Malignant neuroleptic syndrome due to haloperidol. (A case report).
Topics: Adult; Fever; Haloperidol; Humans; Male; Muscle Rigidity; Pallor; Syndrome | 1983 |
Haloperidol: neuroleptic malignant syndrome.
Topics: Adult; Dystonia; Haloperidol; Humans; Male; Muscle Rigidity; Syndrome | 1982 |
[Neuroleptic malignant syndrome. Beneficial effects of dantrolene on hyperthermia and hypertonia (author's transl)].
Topics: Adolescent; Basal Ganglia Diseases; Calcium; Dantrolene; Fever; Haloperidol; Humans; Male; Malignant | 1982 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Con | 1982 |
Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report.
Topics: Adult; AIDS Dementia Complex; Antipsychotic Agents; Astrocytes; Atrophy; Brain; Cell Count; Dystonia | 1994 |
Electrophysiological investigation of thalamic neuronal mechanisms of motor disorders in parkinsonism: an influence of D2ergic transmission blockade on excitation and inhibition of relay neurons in motor thalamic nuclei of cat.
Topics: Action Potentials; Afferent Pathways; Animals; Cats; Cerebellum; Dopamine; Dopamine D2 Receptor Anta | 1994 |
Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level.
Topics: Animals; Antipsychotic Agents; Atropine; Body Temperature Regulation; Cholinergic Antagonists; Creat | 1996 |
Opioid-induced rigidity after intravenous fentanyl.
Topics: Adult; Anesthetics, Intravenous; Antipsychotic Agents; Drug Synergism; Female; Fentanyl; Genitalia, | 1997 |
LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
Topics: Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Excitatory Amino Acid Agonists; Haloperido | 1998 |
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dopamine Antagonists; Electromyography; Excitatory Amino | 1999 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; | 1999 |
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Rel | 2001 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; | 2001 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Comb | 2001 |
Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Electromyo | 2001 |
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Corpus Striatum; Dysk | 2002 |
Behavioral study on the interactions between trazodone and L-dopa.
Topics: Animals; Behavior, Animal; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; | 1979 |
A method for mechanographical recording of muscle tone in the rat: the effect of some antiparkinsonian drugs on rigidity induced by reserpine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Bromocriptine; Carbidopa; Drug Evaluation, Preclinical; | 1978 |
Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: two case reports with a literature review.
Topics: Adolescent; Child; Child Behavior Disorders; Coma; Female; Fever; Haloperidol; Humans; Male; Muscle | 1979 |
An in vivo alpha-2 assay reversal of opioid-induced muscular rigidity and neuroleptic-induced ptosis.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blepharoptosis; Drug Evaluation, P | 1992 |
Involvement of the substantia innominata/ventral pallidum complex in transmitting forelimb muscular rigidity evoked from the nucleus accumbens in rats.
Topics: Animals; Basal Ganglia; Bicuculline; Electrodes; Electromyography; Forelimb; Haloperidol; Injections | 1989 |
Anticatatonic effect of venoruton.
Topics: Animals; Anticoagulants; Antipsychotic Agents; Catatonia; Female; Haloperidol; Hydroxyethylrutoside; | 1988 |
The importance of the striato-nigro-collicular pathway in the expression of haloperidol-induced tonic electromyographic activity.
Topics: Animals; Brain Mapping; Corpus Striatum; Electromyography; gamma-Aminobutyric Acid; Haloperidol; Mal | 1985 |
Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats.
Topics: Animals; Brain Mapping; Catalepsy; Corpus Striatum; Dopamine; Electromyography; Haloperidol; Male; M | 1985 |
Thalamus as a relay station for catalepsy and rigidity.
Topics: Animals; Brain Mapping; Catalepsy; Escape Reaction; Haloperidol; Male; Morphine; Muscimol; Muscle Ri | 1985 |
Cog-wheel rigidity: a prodromal sign of lithium/haloperidol toxicity.
Topics: Adult; Drug Combinations; Haloperidol; Humans; Lithium; Male; Muscle Rigidity | 1986 |
Mechanographic analysis of muscle rigidity after morphine and haloperidol: a new methodological approach.
Topics: Animals; Haloperidol; Male; Morphine; Muscle Rigidity; Muscle Tonus; Naloxone; Rats; Rats, Inbred St | 1987 |
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Levodop | 1987 |
Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Female; Haloperidol; Hu | 1986 |
On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.
Topics: Animals; Drug Tolerance; Haloperidol; Male; Morphine; Motor Activity; Muscle Rigidity; Naloxone; Rat | 1986 |
Rigidity and tremor induced in feline muscles deprived of their fusiomtor control.
Topics: Achilles Tendon; Animals; Animals, Newborn; Cats; Disease Models, Animal; Electromyography; Haloperi | 1974 |
Fine structure of the cilia of rotifers.
Topics: Basal Bodies; Cilia; Cranial Nerves; Cytoskeleton; Dissent and Disputes; Epoxy Resins; Eye Enucleati | 1961 |